SRR1419893
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.524
- INTERFERON_GAMMA_RESPONSE+0.437
- ANGIOGENESIS+0.427
- IL6_JAK_STAT3_SIGNALING+0.417
- INFLAMMATORY_RESPONSE+0.314
- ALLOGRAFT_REJECTION+0.306
- TNFA_SIGNALING_VIA_NFKB+0.235
- COAGULATION+0.228
- IL2_STAT5_SIGNALING+0.192
- COMPLEMENT+0.173
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.471
- UV_RESPONSE_DN-0.403
- OXIDATIVE_PHOSPHORYLATION-0.399
- PROTEIN_SECRETION-0.280
- NOTCH_SIGNALING-0.269
- UNFOLDED_PROTEIN_RESPONSE-0.266
- MYC_TARGETS_V2-0.257
- DNA_REPAIR-0.239
- MYC_TARGETS_V1-0.221
- ADIPOGENESIS-0.188
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1079168 | GTEX | — | 0.900 |
| 2 | SRR1323807 | GTEX | — | 0.894 |
| 3 | SRR1330546 | GTEX | — | 0.892 |
| 4 | SRR615020 | GTEX | — | 0.886 |
| 5 | SRR1315994 | GTEX | — | 0.882 |
| 6 | SRR1369219 | GTEX | — | 0.882 |
| 7 | SRR1310623 | GTEX | — | 0.864 |
| 8 | SRR1396659 | GTEX | — | 0.862 |
| 9 | SRR1073755 | GTEX | — | 0.858 |
| 10 | SRR608598 | GTEX | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.524 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.437 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.427 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.417 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.314 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.306 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.235 | Inavolisib | — uncovered |
| COAGULATION | 0.228 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.192 | Idelalisib | — uncovered |
| COMPLEMENT | 0.173 | Inavolisib | — uncovered |
| MYOGENESIS | 0.149 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.144 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.132 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.089 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.086 | Remibrutinib | — uncovered |
| PEROXISOME | 0.051 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.038 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.036 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.034 | Temsirolimus | — uncovered |